Sugi Predict

Sugi Predict / Compounds / SCHEMBL6166429

SCHEMBL6166429

SCHEMBL6166429

CCOC(=O)c1ccc(OC(C(=O)OC(C)(C)C)C2CCNCC2)c(OC)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.48
▸ ALDH1A1 P00352 4/20 0.48
▸ MAPK1 P28482 1/20 0.48
▸ HSD17B2 P37059 1/20 0.45
▸ LMNA P02545 2/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.42
▸ RAB9A P51151 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ TSHR P16473 2/20 0.42
▸ ALOX15 P16050 2/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ CASP7 P55210 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ KMT2A Q03164 4/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ GAA P10253 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ PDE4A P27815 1/20 0.39
▸ PDE4B Q07343 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6168405 0.88 CA12 (0.46) MAPK1LMNARAB9ATSHRHTT
SCHEMBL6222829 0.84 MAPT (0.56) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL7395783 0.75 KMT2A (0.41) ALDH1A1SMN1; SMN2HSD17B10KMT2AGAA
SCHEMBL7684319 0.74 MAPT (0.77) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL7401892 0.73 OXTR (0.39) MAPTALDH1A1RAB9ANPC1KMT2A
SCHEMBL5153148 0.72 CA12 (0.44) TSHRKMT2AHTTMEN1KDM4E
SCHEMBL30506315 0.71 HSD17B2 (0.76) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL1660365 0.71 HSD17B2 (0.76) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL11341115 0.71 MAPT (0.61) MAPTALDH1A1MAPK1HSD17B2LMNA
SCHEMBL27387024 0.71 CPN1 (0.38) ALDH1A1TSHRKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1592423-A2 COMBINATION THERAPY OF ZD6474 WITH 5-FU AND/OR CPT-11 Astrazeneca AB (SE) 2005-11-09 — — EP disclosed
EP-1534287-A1 COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER Astrazeneca AB (SE) 2005-06-01 — — EP disclosed
WO-2004071397-A2 COMBINATION THERAPY OF ZD6474 WITH 5-FU OR/AND CPT-11 ASTRAZENECA AB (SE) 2004-08-26 — — WO disclosed
EP-1446124-A1 COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE AstraZeneca AB (SE) 2004-08-18 — — EP disclosed
WO-2004014383-A1 COMBINATION OF ZD6474, AN INHIBITOR OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR, WITH RADIOTHERAPY IN THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2004-02-19 — — WO disclosed
WO-2003039551-A1 COMBINATION THERAPY COMPRISING ZD6474 AND A TAXANE ASTRAZENECA AB (SE) 2003-05-15 — — WO disclosed
EP-1244647-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS AstraZeneca AB (SE) 2002-10-02 — — EP disclosed
EP-1218355-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2002-07-03 — — EP disclosed
EP-1218354-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS AstraZeneca AB (SE) 2002-07-03 — — EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 — — EP disclosed
EP-1119567-A1 QUINAZOLINE DERIVATIVES AstraZeneca AB (SE) 2001-08-01 — — EP disclosed
WO-2001032651-A1 QUINAZOLINE DERIVATIVES AS VEGF INHIBITORS ASTRAZENECA AB (SE) 2001-05-10 — — WO disclosed
WO-2001021596-A1 QUINAZOLINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS ASTRAZENECA AB (SE) 2001-03-29 — — WO disclosed
WO-2001021597-A1 THERAPEUTIC QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2001-03-29 — — WO disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 — — WO disclosed
WO-2000021955-A1 QUINAZOLINE DERIVATIVES ASTRAZENECA AB (SE) 2000-04-20 — — WO disclosed